Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2024
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Read more at globenewswire.com11.85
-1.65 (-12.22%)
Find more stocks in the Stock Screener
LYRA Latest News and Analysis
4 days ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
10 days ago - ChartmillWhat's going on in today's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
10 days ago - ChartmillWhich stocks are moving on Tuesday?Curious about what's happening in today's session? Check out the latest stock movements and price changes.
